Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Inhalation Sciences signs collaboration agreement with leading Indian multinational pharma company

Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respiratory portfolio and a major presence in over 80 markets worldwide. The company has chosen DissolvIt[®],[ ]ISAB’s in vitro dissolution and absorption module, for its Inhalation Research project.The company is ISAB’s first Indian client and is a highly agile, innovative multinational with a large number of development projects ongoing and a YoY R&D investment that has grown continuously over recent years. The Indian pharmaceutical industry as a whole is a

Nordea Bank Abp flagging notification: BlackRock Inc.’s shareholding decreases below threshold of five percent

Nordea Bank AbpStock exchange release – Major shareholder announcements29 September 2023 at 9.45 EET BlackRock, Inc.'s indirect shareholding of Nordea Bank Abp’s shares and voting rights has decreased below the threshold of five percent, according to a notification Nordea received on 28 September 2023 under Chapter 9, Section 10 of the Securities Markets Act (SMA). The threshold was crossed on 27 September 2023. The total number of shares and voting rights in Nordea Bank Abp is 3,557,459,330. Total positions of BlackRock, Inc. and its funds according to the notification: +---

LKAB Malmtrafik extends its contract with Railcare for transporting iron ore, worth a total of approximately SEK 70 million

LKAB Malmtrafik is exercising its option to extend the contract with Railcare relating to iron ore transports until 31 December 2024. The value of the contract during 2024 amounts to approximately SEK 70 million.“LKAB is a key customer and it is very pleasing that they are exercising the option to extend the agreement throughout 2024. The early announcement that the option will be exercised provides good foresight in the planning of resources and ensures that the transports can take place without interruption. In the new contract, we will also equip all locomotives with central coupling,

Bonava to carry out measures to strengthen competitiveness

To strengthen the company’s long-term competitiveness and increase profitability, Bonava intends to implement restructuring measures in Germany, and continue adaptations in Sweden and Finland. It is estimated that this will affect 400 positions. The measures are expected to yield annual savings of SEK 400 M from 1 January 2025, and a restructuring cost of SEK 350 M will be recognised in the third quarter of 2023.The situation in the market for newbuilt housing remains challenging. Sales have stabilised but at low levels, which will result in reduced production volumes going forward. Since

New committee chair and new employee representative appointed to Nordea’s Board of Directors

Nordea Bank AbpStock exchange release – Changes board/management/auditors29 September 2023 at 9.30 EET Birger Steen has stepped down as Chair of the Board Operations and Sustainability Committee (BOSC) and will continue as an ordinary member. Kjersti Wiklund, current member of the committee, has been appointed Chair of the committee. The employees of the Nordea Group have appointed Kasper Skovgaard Pedersen as an ordinary member of the Board of Directors until the end of the next Annual General Meeting. Dorrit Groth Brandt, an ordinary member of the Board of Directors appointed by

Cereno Scientific’s Board, management and scientific advisors have subscribed warrants within the framework of the incentive programs

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that members of the company's Board and management as well as scientific advisors have signed warrants within the framework of the incentive programs that were introduced at the extraordinary general meeting held on September 14, 2023.“With the company's upcoming data quality control of CardioMEMS in the Phase II study with CS1 in PAH during Q4 2023, which also gives us the opportunity to report early efficacy data, it is a strong statement

New number of shares and votes in Moberg Pharma AB (publ)

Moberg Pharma AB (publ) (the "Company") today announces that the number of shares in the Company has increased to a total of 28,407,452 due to the completion of the rights issue of units, consisting of ordinary shares and warrants of series 2023:1, resolved by the Board of Directors on 28 June 2023 (the "Rights Issue") and due to the completion of the directed issue of units, consisting of ordinary shares and warrants of series 2023:1, to guarantors in the Rights Issue who chose to receive their guarantee commission in the form of units (the "Remuneration Issue").The Rights Issue has

Annexin announces success in the company's cancer initiative

Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells.Within the framework of Annexin's cancer initiative, the company has successfully produced a so-called conjugate where the drug candidate ANXV is chemically bound to a chemotherapy agent and together forms a new composite molecule. In cell systems outside the body, this ANXV conjugate has been shown to kill a type of cancer cell taken from a person with triple-negative

Change of number of shares and votes in Truecaller AB (publ)

The number of shares and votes in Truecaller AB (publ) (“Truecaller”) has changed during September 2023 as a result of exercise of employee stock options of series 2021:3 and series 2021:6 in accordance with Truecaller's incentive programs.Through the exercise of the employee stock options, the number of shares has increased by 1,627,794 and the share capital has increased by SEK 3,255.588. As of 29 September 2023, the last trading day of September, the number of shares in Truecaller amounts to 381,187,504, of which 46,783,800 are ordinary shares of series A with 10 votes per share, 328,803,

Brain+ A/S announces the exercise price for its warrants of series TO 2

COMPANY ANNOUNCEMENT Copenhagen, Denmark, September  29, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. · The exercise price of the TO 2 warrants has been set at DKK 0.20 · The exercise period for the TO 2 warrants

Swedavia opens new Marketplace with food and shopping at Arlanda

Swedavia is making a major investment in developing the commercial offering at Stockholm Arlanda Airport. This will now be especially clear when the first part of the brand-new Marketplace in Terminal 5 opens its doors. The long-term strategy behind this venture has a focus on variation, renewal and value for money. The Marketplace now opening in Terminal 5 will be the heart of Arlanda’s commercial offering. It provides a variety of food, beverages, shopping and services concentrated in an area with 11,000 square metres of floorspace right next to the new state-of-the-art security

Crayfish BidCo Oy extends offer period under its tender offer for Caverion Corporation until 1 November 2023; expects to obtain remaining merger control clearance in Finland in October

Caverion Corporation Tender Offer 29 September 2023 at 9:05 a.m. (EEST)Crayfish BidCo Oy extends offer period under its tender offer for Caverion Corporation until 1 November 2023; expects to obtain remaining merger control clearance in Finland in October NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, PLEASE SEE SECTION ENTITLED “IMPORTANT INFORMATION”

Change in the number of shares and votes in AcadeMedia

The number of shares and votes in AcadeMedia AB has during September 2023 increased through conversion of convertible bonds relating to the convertible program for employees within the AcadeMedia group, adopted at the Annual General Meeting on 22 November 2018. In total, the number of shares and votes has increased by 84 ordinary shares and as many votes. Today, the last trading day of the month, there are in total 105,793,466 shares in AcadeMedia. 105,587,561 shares are ordinary shares with one vote per share and 205,905 shares are C shares with one tenth of a vote per share. The total

Increased number of shares and voting rights in Catena Media plc

Catena Media plc announces that the number of shares and voting rights in the company has increased by 3,462 due to the exercise of Catena Media’s warrants (CTM TO1) during the 14th warrant exercise period that followed publication of the interim report for the second quarter of 2023. As announced on 5 September 2023, 3,462 warrants were used to subscribe for the same number of new ordinary shares in Catena Media during the 14th warrant exercise period. The new shares were then registered with the Maltese authorities. As of 29 September 2023, the last trading day of the month, the

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In September, at the request of shareholders, 792 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,252,764,912. The total number of registered shares in the company amounts to 702,342,489 of which 61,158,047 are Class A

John Mattson appoints new CFO

John Mattson has appointed Ebba Pilo Karth as the company’s new CFO. She will assume her role by 1 April 2024 at the latest and will also join company management at that time. Until that time, Eva Wiklund will hold the role of interim CFO. In August 2023, Maria Wirén assumed the role of Head of Property Management and is now a member of John Mattson’s company management.The incoming CFO, Ebba Pilo Karth, joins us most recently from Forsen AB, where she has held the role of CFO since 2021. Prior to that, she held the roles of Chief Financial Officer of Stena Fastigheter Stockholm AB and as

Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) (“Sobi”) has, as previously announced, carried out a rights issue of common shares, which has resulted in changes in the number of shares and votes in Sobi.Through the rights issue, the final outcome of which was announced in a press release on 19 September 2023, the number of common shares has increased by 42,419,668, corresponding to an equal number of votes. As of 29 September 2023, the total number of shares in Sobi amounts to 353,756,464 shares, corresponding to an equal number of votes. All shares are common shares. As of 29

MediCrops acquires Swiss Alpinopharma.

A strategic move to enhance digital patient care in the booming European cannabis market.(Pfäffikon, Schwyz/Berlin) – International Swiss-based health tech company MediCrops Holding AG (‘MediCrops’) has acquired Berlin-based company Swiss Alpinopharma GmbH (‘Swiss Alpinopharma’), a disruptive market leader in the field of medical cannabis and owner of telemedicine platform Enmedify . Swiss Alpinopharma also offers doctors-certified CME training on the use of medical cannabis. The acquisition consolidates MediCrops’ position in a European market that is expected to

Aurubis AG and Metso working on the decarbonization of Hamburg copper smelter

Metso Corporation’s press release on September 29, 2023, at 09:00 a.m. EESTAurubis AG announced in August 2023 their decision to invest in hydrogen-ready anode furnaces at their Hamburg copper processing plant in Germany. The company relies on Metso’s proven technology, consisting of complete hydrogen-ready Outotec Anode Furnaces with hoods and auxiliary equipment, which will be used in the anode refining process. Close collaboration with Aurubis was key in designing the hydrogen-ready furnace by Metso, a first in the copper industry. Design input was based on full-scale hydrogen testing

Viaplay Group and Formula 1 agree strategic partnership in the Netherlands

· Access to F1 TV Pro service to be included in Viaplay subscriptions in the Netherlands to the benefit of all Viaplay sports subscribers in the country · Agreement reinforces Viaplay’s leadership position as the Dutch home of the world’s biggest and most popular live sports · Strategic partnership will be supported by an innovative business model Viaplay Group and Formula 1 have entered a strategic partnership in the Netherlands that will see Viaplay customers able to access F1 TV Pro as part of their Viaplay subscriptions, alongside Viaplay’s world-class Formula 1 coverage and

Nevisense detects skin barrier damage from skin models in research

STOCKHOLM, SWEDEN, — September 29, 2023 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. The study is the first to use Nevisense to measure skin barrier function in human excised skin samples, demonstrating Nevisense as an effective laboratory research device.Skin barrier research comprises one of the fastest-growing fields within the dermatology community,

DexTech Medical AB, Invitation to open Annual General Meeting and notice

On Tuesday, October 31, 2023, DexTech Medical AB ("DexTech") will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, the founders, CEO Anders R Holmberg and Medical Director Professor Sten Nilsson, will present the company and the current clinical situation regarding prostate cancer. There will be an opportunity to ask questions to DexTech's board and management. Formal notice of the Annual General Meeting is available further down in this press release. Notification for non-shareholders shall

There are no items matching the current filter
There are no more items matching the current filter
Back to top